Inhibitory potency of tacrolimus ointment on skin tumor induction in a mouse model of an initiation-promotion skin tumor

Journal of Dermatology

Volumn 38, Issue 6, 2011, Pages 562-570

  Mitamura, Takashi ^a,e   Doi, Yuko ^b   Kawabe, Mayumi ^b   Lilja, Herman ^c   Motomura, Masatsugu ^a   Oishi, Yuji ^a   Yoshizawa, Katsuhiko ^d   Seki, Jiro ^a  

^a Drug Safety Research Laboratories   (Japan)

^b Daiyukai Research Institute for Medical Science   (Japan)

^c Astellas Pharma Global Development   (United States)

^d KANSAI MEDICAL UNIVERSITY   (Japan)

^e NONE   (Japan)

Author keywords

atopic dermatitis; skin carcinogenesis; skin tumor initiation promotion mouse model; tacrolimus ointment; topical immunosuppressant

Indexed keywords

MACROGOL; TACROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CARCINOGEN TESTING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HYPERPLASIA; MOUSE; NONHUMAN; OINTMENT; SKIN CARCINOGENESIS; SKIN DEFECT; SKIN NODULE; SKIN TUMOR; TUMOR PROMOTION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENICITY TESTS; FEMALE; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED ICR; OINTMENTS; SKIN; SKIN NEOPLASMS; TACROLIMUS;

EID: 79957923612     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/j.1346-8138.2010.01046.x     Document Type: Article

References (23)

1. Schreiber SL, Crabtree GR,. The mechanism of action of cyclosporine A and FK506. Immunol Today 1992; 13: 136-142.
2. Sakuma S, Higashi Y, Sato N, et al. Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system (comparison with steroids). Int Immunopharmacol 2001; 1: 1219-1226. (Pubitemid 32434437)
3. Hirai O, Miyamae Y, Izumi H, Miyamoto A, Noguchi H,. Mutagenicity Test of Tacrolimus (FK506). The Clinical Report 1992; 26: 989-1001.
4. Niwa Y, Terashima T, Sumi H,. Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin. Br J Dermatol 2003; 149: 960-967. (Pubitemid 37541979)
5. Jiang H, Yamamoto S, Nishikawa K, Kato R,. Anti-tumor-promoting action of FK506, a potent immunosuppressive agent. Carcinogenesis 1993; 14: 67-71. (Pubitemid 23152745)
6. Slaga TJ, Bowden GT, Scribner JD, Boutwell RK,. Dose-response studies on the ability of 7,12-dimethylbenz(a) anthracene and benz(a) anthracene to initiate skin tumors. J Natl Cancer Inst 1974; 53: 1327-1340.
7. Slaga TJ, Fisher SM, Triplett LL, Nesnow S,. Comparison of complete carcinogenesis and tumor initiation and promotion in mouse skin: the induction of papilloma by tumor initiation-promotion-a reliable short-term assay. J Environ Pathol Toxicol 1981; 4: 1025-1041.
8. DiGiovanni J, Slaga TS, Fischer SM,. Strain differences and solvent effects in mouse skin carcinogenesis experiments using carcinogens, tumors initiators and promoters. Prog Exp Tumor Res 1983; 26: 85-109.
9. National Toxicology Program (NTP). Comparative Initiation/Promotion Skin Paint Studies of B6C3F1 Mice, Swiss (CD-1) Mice, and Sencar Mice. NTP TR441, NIH Publication No. 96-3357, Research Triangle Park, NC, USA, 1996.
10. Williams GM, Iatropoulos MJ, Enzmann HG,. Principles of testing for carcinogenic activity. In:, Wallace Hayes, Ed. Principles and Methods of Toxicology, 5th edn. Taylor & Francis: Philadelphia, PA, USA, 2008; 1265-1316.
11. Japanese Ministry of Health and Welfare. Good Laboratory Practice Principles, Ordinance No. 21, 1997.
12. Notification No. 6, 27 March 1980, Prime Minister's Office, Japan
13. Bartlett MS,. Properties of sufficiency and statistical tests. Proc R Soc Lond A Math Phys Sci 1937; 160: 268-282.
14. Fisher RA,. Statistical methods and scientific induction. J Royal Stat Soc Series B 1955; 17: 69-78.
15. Gad SC, Weil CS,. Statistics for toxicologists. In:, Hayes AW, Ed. Principles and Methods of Toxicology. Raven Press Ltd, 1989; 435-483.
16. Ghadially FN,. The role of the hair follicle in the origin and evolution of some cutaneous neoplasms of man and experimental animals. Cancer 1961; 14: 801-816.
17. Greaves P,. Histopathology of Preclinical Toxicity Studies. Elsevier Inc, New York, USA, 2007; pp. 31-36.
18. Ward JM, Goodman DG, Squire RA,. Neoplastic and non-neoplastic lesions in aging ((57BL/6NxC3H/Hen)F1B6C3F1) mice. J Natl Cancer Inst 1979; 63: 849-854. (Pubitemid 10225016)
19. Hung M, Ma W, Yen P, Xie J, Han J,. Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylpholbol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein HeLa cells. Carcinogenesis 1996; 17 (4): 761-765. (Pubitemid 26129690)
20. Morikawa T, Wanibuch H, Morimura K, Ogawa M, Fukushima S,. Promotion of skin carcinogenesis by dimethylarsinic acid in Keratin (K6)/ODC transgenic mice. Jpn J Cancer Res 2000; 91: 579-581. (Pubitemid 30453783)
21. Inai K, Aoki Y, Akamizu H, Eto R, Nishida T, Tokuoka S,. Tumorigenicity study of butyl and isobutyl p-hydroxybenzoates administered orally to mice. Food Chem Toxicol 1985; 23 (6): 575-578. (Pubitemid 15013599)
22. Ishikawa T, Nakatsuru Y, Zarcovic M, Shamsuddin AM,. Inhibition of skin cancer by IP6 in vivo: Initiation-promotion model. Anticancer Res 1999; 19: 3749-3752.
23. Wei H, Bowen R, Zhang X, Lebwohl M,. Isoflavone gestein inhibits the initiation and promotion of two-stage skin carcinogenesis in mice. Carcinogenesis 1998; 19: 1509-1514. (Pubitemid 28409852)